Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal

All NewsMarch 25, 2025

Axsome’s solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent